Creso looks to expand product range following successful Swiss launch
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH) has today informed the market of its commitment to expand the commercialisation and distribution of anibidiol®, its CBD-based complementary animal feed product.
These plans come on the heels of the product’s successful launch in Switzerland in November 2017 — which it conducted with animal pharmaceutical giant Virbac Switzerland — resulting in early revenue for the company (already banked) and generated positive feedback from customers and veterinarians.
CPH is now in the process of planning the commercialisation of the anibidiol® range across global markets in CY2018 and beyond. This product expansion will involve tapping into the significant US$9.8 billion global companion animal market.
However, how much of the market CPH is able to corner is speculative at this stage and therefore investors shouldn’t act on this fact alone, but should take all publicly available information into account and seek professional financial advice.
Managing Director of Virbac Switzerland Rolf Heeb commented on the news: "We have been assured by the interest from vets that it was the right move and the right time to launch anibidiol®. There has been great interest from both vets and pet owners since its launch."
Swiss veterinarian Dr Fabian Huwiler provided support for this view, stating of the product: “anibidiol® is a unique natural, organic and efficient feed supplement improving the quality of life of the pet and the pet owner; we were waiting for such a product.”
According to CPH’s announcement, the global animal health market is valued at US$30 billion and is projected to continue to grow at a fast pace; with 41 percent of pet owners considering or trying out various alternative therapies for their pets.
In commenting on these developments, CPH Co-Founder and Chief Executive Officer Dr Miri Halperin Wernli said: “This promising start with anibidiol® in Switzerland sets a very sound foundation for Creso Pharma to progress into the international market arena.”
CPH is in the process of expanding the anibidiol® range through the development of additional lifecycle products for companion animals. It plans to team up again with Swiss pharmaceutical animal health company Virbac for further launches in Switzerland in 2018.
About anibidiol®
anibidiol® is a natural complementary feed for pets which contains full spectrum hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant, as well as hemp seed oil. anibidiol® is a proprietary product which combines not only CBD, but fatty acids Omega 3, Omega 6 and Omega 9, as well as terpenes, flavonoids, and other active herbal ingredients.
The product’s ingredients interact in a complex way which, in the words of the company, “enhances their overall health-promoting effect”. anibidiol® is the first Swiss Agroscope conformed complementary feed for companion animals that contains natural hemp extract with CBD and is THC-free.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
